Table 1.
Comparison of demographic and clinical data between DLB and AD cohorts
| Characteristic | DLB (n=251) | AD (n=222) | χ2 or F test statistic | p Value |
| Gender | ||||
| Female | 129 (51.4%) | 139 (62.6%) | χ2 1 = 6.04 | 0.01 |
| Male | 122 | 83 | ||
| Age at first presentation with cognitive impairment (years) | 78.8 (SD 7.7) (n=251) | 79.5 (SD 8.8) (n=200) | F1,449 =2.51 | 0.11 |
| Age at diagnosis (years) | 79.3 (SD 7.6) | 80.2 (SD 8.8) | F1,471 =1.32 | 0.25 |
| MMSE score at diagnosis | 20.1 (SD 5.5) (n=183) | 20.6 (SD 4.9) (n=172) | F1,353 <1 | 0.41 |
| Charlson comorbidity index at diagnosis | ||||
| Low comorbidity (score ≤2) | 183 (72.9%) | 158 (71.2%) | χ2 1 = 0.18 | 0.67 |
| High comorbidity (score >2) | 68 | 64 | ||
| Medications prescribed | ||||
| Antipsychotic (neuroleptic) drugs | 103 (41.0%) | 32 (14.4%) | χ2 1 = 39.6 | <0.0001 |
| Parkinson’s disease drugs | 93 (37.1%) | 0 (0%) | χ2 1 = 102.39 | <0.0001 |
| Antidementia drugs | 152 (60.6%) | 139 (62.6%) | χ1 = 0.21 | 0.65 |
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination.